Reviva Pharmaceuticals Holdings (RVPH) Non Operating Interest Expenses (2023 - 2026)

Reviva Pharmaceuticals Holdings has disclosed Non Operating Interest Expenses across 4 years of filings, most recently posting $2935.0 for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses fell 38.82% year-over-year to $2935.0; the TTM figure through Jun 2026 stood at $6573.0 (down 74.98% YoY), while the FY2025 annual figure was $13402.0, down 27.55% from the prior year.
• Non Operating Interest Expenses came in at $2935.0 for Q2 2026 at Reviva Pharmaceuticals Holdings, down from $6653.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $13311.0 in Q4 2023 to a low of -$5620.0 in Q4 2025.
• Average Non Operating Interest Expenses over 4 years is $5793.8, with a median of $5149.5 recorded in 2024.
• The largest YoY upside for Non Operating Interest Expenses was 233.24% in 2025 against a maximum downside of 219.3% in 2025.
• Over 4 years, Non Operating Interest Expenses stood at $13311.0 in 2023, then sank by 64.61% to $4711.0 in 2024, then slumped by 219.3% to -$5620.0 in 2025, then jumped by 152.22% to $2935.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $2935.0 in Q2 2026, $6653.0 in Q1 2026, and -$5620.0 in Q4 2025.